Get the Stockscreener App
43.41
0.72%
-0.58
Cytokinetics Inc stock is traded at $43.41, with a volume of 214.10K.
It is down -0.72% in the last 24 hours and up +4.93% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$43.99
Open:
$43.74
24h Volume:
214.10K
Relative Volume:
0.15
Market Cap:
$5.11B
Revenue:
$3.22M
Net Income/Loss:
$-576.40M
P/E Ratio:
-8.0688
EPS:
-5.38
Net Cash Flow:
$-407.05M
1W Performance:
+0.93%
1M Performance:
+4.93%
6M Performance:
-21.85%
1Y Performance:
-32.43%
1-Day Range:
$43.32
$44.07
1-Week Range:
$42.04
$45.07
52-Week Range:
$40.53
$75.71
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
43.47 | 5.11B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks
Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com
Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks
Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise
Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Canada
Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com
Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com
Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India
Cytokinetics Executives Engage in Stock Transactions - TradingView
Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK
Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK
What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World
Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks
Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks
Cytokinetics Executives Cash In: Massive Stock Sales Unveiled! - TipRanks
Insider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus.com
Cytokinetics EVP Callos sells $47,768 in stock - Investing.com
Cytokinetics CEO Robert Blum sells $1.08 million in stock - Investing.com
Cytokinetics EVP Callos sells $47,768 in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics EVP sells $85,000 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $85,000 in stock - Investing.com India
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus - MSN
Cytokinetics to Participate in March Investor Conferences - The Manila Times
Where Can You Hear Cytokinetics' Latest Strategy? Three Upcoming Investor Conferences Revealed - StockTitan
Cytokinetics’ (CYTK) Buy Rating Reiterated at HC Wainwright - Defense World
New York State Common Retirement Fund Boosts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Brokers Set Expectations for Cytokinetics Q1 Earnings - Defense World
Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Impax Asset Management Group plc Acquires 50,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Smart Money Is Betting Big In CYTK Options - Benzinga
Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating - Marketscreener.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2024 Earnings Call Transcript - Insider Monkey
Cytokinetics’ Mixed Outlook: Hold Rating Amid Execution Challenges and Modest Trial Impact - TipRanks
Principal Financial Group Inc. Sells 1,949 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics’ Earnings Call: Progress Amid Challenges - TipRanks
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses - Yahoo Finance
Cytokinetics’ Promising Pipeline and Strategic Expansion Drive Buy Rating - TipRanks
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Mar 06 '25 |
Sale |
43.27 |
8,228 |
356,026 |
105,394 |
| Blum Robert I | President & CEO |
Mar 06 '25 |
Sale |
43.44 |
16,970 |
737,177 |
364,181 |
| Blum Robert I | President & CEO |
Mar 05 '25 |
Sale |
43.23 |
25,000 |
1,080,750 |
381,151 |
| Malik Fady Ibraham | EVP Research & Development |
Mar 03 '25 |
Sale |
42.88 |
2,449 |
105,013 |
113,622 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 03 '25 |
Sale |
42.88 |
1,114 |
47,768 |
67,775 |
| Blum Robert I | President & CEO |
Mar 03 '25 |
Sale |
42.88 |
8,743 |
374,900 |
406,151 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):